It inhibits AChE and β-secretase enzymes. It has been shown to act at a dose of 20 mg/kg in combination with quercetin and increase the neuroprotective effect of quercetin. In the ethylcholine aziridinium-induced AD model, which mimics the cholinergic hypofunction display in Alzheimer’s disease, it lowered the cognitive deficits and hippocampal neurodegeneration linked with this AD model. These effects may possibly be due to their antioxidant and anti-inflammatory activities. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.